Newstral
BIIB
- MBiogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug2 min readmarketwatch.com
- IBiogen‘s Alzheimer treatment triggers debate regarding its real-world benefitsinvezz.com
- BStreet Shrugs Off FDA's Call for Probe of Alzheimer's Drug Approval3 min readbarrons.com
- MFDA calls for investigation into its own approval of Biogen's Alzheimer's drug2 min readmarketwatch.com
- BFDA Narrows Its Label on Biogen's Alzheimer's Drug a Month After Approving It3 min readbarrons.com
- BEli Lilly Stock Soared on Alzheimer's Hopes. Now Wall Street Has Doubts.3 min readbarrons.com
- IBiogen skyrockets after Alzheimer’s drug approval – time to buy?invezz.com
- MFDA approved the first major Alzheimer’s treatment in 18 years — what that means for your loved ones fighting the disease 4 minmarketwatch.com
- The FDA Approves The Alzheimer’s Drug Aducanumab — And Reminds Us Of The Herculean Task Of Medicare ReformForbes
- BBiogen Stock Jumps on FDA Approvalbarrons.com
- FDA approves Biogen’s Alzheimer’s drug, the first to slow the diseasewsj.com
- MBiogen’s pivotal moment: Will the FDA approve the experimental — and controversial — Alzheimer's-disease drug aducanumab?marketwatch.com
- BDip in Eli Lilly Stock Makes It a Buy, Analyst Saysbarrons.com
- BEli Lilly Makes a Case For Its Alzheimer's Drug as Shares Dropbarrons.com
- BEli Lilly Will Unveil Alzheimer's Drug Data Next Week. What to Watch.barrons.com
- BBiogen Stock Is Falling Because Earnings Guidance Came Up Shortbarrons.com
- BLilly Reports Strong Sales, Boosted by Covid Antibodiesbarrons.com
- BVir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up Againbarrons.com
- Here’s Why Biogen Stock Can Offer Over 35% GainsForbes
- Warren Buffett Dials Down DaVita StakeForbes
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.